Spruce Biosciences, Inc. (SPRB): Price to Sales

Corporate company logo of Spruce Biosciences (SPRB)

The smoothed P/S of Spruce Biosciences (SPRB) reflects the impact of a stable staff of biochemists and a set of regulators. This trend is driven by the development of drugs for rare endocrine disorders with expansion across Europe and the US. The implementation of ESG filters and energy saving at facilities also influences the valuation. The current level of 85.10 determines the latest market valuation metric for each unit of sales.

Spruce Biosciences - SPRB P/S Multiple (period 05/21/2023 - 03/09/2026)

Metric breakdowns and analytics for Spruce Biosciences (SPRB)

- current price and projected stock value:
Price Chart Spruce Biosciences Inc.|SPRB - Price Target Chart
- stock exchange capitalization data:
Market Value Spruce Biosciences|SPRB - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Spruce Biosciences|SPRB - Book Capitalization|Market Capitalization to Book Value sprucebiosciences.com|SPRB - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient Spruce Biosciences|SPRB - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio sprucebiosciences.com|SPRB - Company Debts|Debts to Net Assets Spruce Biosciences|SPRB - Company Long-Term Debt|Current Liabilities Spruce Biosciences|Intermediate Coverage Ratio sprucebiosciences.com
- financial results and valuation multiples details:
SPRB - Net Income|Projected Future Earnings Spruce Biosciences|SPRB - P/E Multiple|Projected Price to Earnings Spruce Biosciences Inc.|SPRB - PEG Multiple|Company Value to EBITDA Spruce Biosciences|SPRB - Operating profit before deduction of amortization|Earnings per share for the trailing year Spruce Biosciences|SPRB - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months sprucebiosciences.com|SPRB - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Spruce Biosciences
- issuer revenue and sales details:
SPRB - Company Revenue|Company Expected Sales Volume sprucebiosciences.com|SPRB - Price-to-Revenue Ratio|Market Cap to Expected Sales Ratio Spruce Biosciences
Fundamental company analysis:SPRB, Spruce Biosciences Inc.
Core merchandise of Spruce Biosciences, Inc.

The use of automated biodata collection in Spruce Biosciences (SPRB) trials directly impacts operational efficiency, which is reflected in the price-to-sales ratio dynamics. This multiple compares the company's market capitalization to its annual sales volume, allowing investors to determine the asset's degree of overvaluation and assess the extent to which the current share price is justified by actual cash flows from product sales.

Competitors of Spruce Biosciences

Price-to-Revenue Ratio ASND (ascendispharma.com)|Price-to-Revenue Ratio Madrigal Pharmaceuticals, Inc. MDGL|Corcept Therapeutics Inc. (CORT) - Price to Sales|RYTM - Price-to-Revenue Ratio|AKRO: Price-to-Revenue Ratio|MTSR: P/S Multiple|MLTX - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Crinetics|NewAmsterdam Pharma Company (NAMS) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Soleno (SLNO)|Market Cap to Revenue Amicus Corp FOLD|Price-to-Revenue Ratio 89bio, Inc. ETNB|Price-to-Revenue Coefficient agios.com (AGIO)|GPCR - Price-to-Revenue Ratio|Price-to-Sales Ratio MDXG|Rezolute Corp (RZLT) - Price-to-Revenue Ratio|Lexicon Corp - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue MBX|P/S Multiple altimmune.com|P/S Multiple AARD|Market Cap to Revenue Sagimet Biosciences, Inc. SGMT|P/S Multiple BIOA (BioAge Labs Inc.)|Biomea Fusion Corp (BMEA) - Price to Sales|QNCX: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio GUTS (fractyl.com)|VTVT: P/S Multiple|ATPC (Agape ATP) - Price-to-Revenue Ratio|PLUR (Pluristem Therapeutics) - P/S Multiple|Synlogic Corp (SYBX) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Lipocine Inc. (LPCN)|MTNB - Price to Sales|Price-to-Revenue Ratio Galecto GLTO|Price-to-Revenue Coefficient Carmell Corp. (CTCX)|Lumos Pharma Corp - P/S Multiple|Organovo Corp (ONVO) - Market Cap to Revenue|RDUS: P/S Multiple